• Revenue segment mix: Biocon's biopharma business accounts for approximately 83% of total revenue and drove 10% year-on-year growth alongside a generic turnaround, while research services (Syngene) contributed 17% and declined 16% due to lower demand from a major biologics client.
• Biosimilar growth drivers: Second-half growth is expected to accelerate, driven by product rollouts including Yesintech achieving over 20% US market share, Bevacizumab, Insulin Aspart (Kirsty), and newly launched Aflibercept (Yesafili).
• R&D and margins: Full-year R&D investments are projected to remain around the 7% mark despite development cycle fluctuations, with the company aiming to consistently maintain margins in the mid-20s range.
• Legacy product durability: Unlike standard generics, mature biosimilars such as Pegfilgrastim and Trastuzumab continue to deliver healthy and durable margins nearly eight years after launch.